To access this element change to forms mode OFF
Grant Award View - GA217900
REMIT: An international, multi-centre, randomised clinical trial to...
GA ID:
GA217900
Agency:
Department of Health and Aged Care
Approval Date:
6-Dec-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Feb-2022 to 31-Jan-2027
Value (AUD):
$2,904,210.20
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
REMIT: An international, multi-centre, randomised clinical trial to compare Obinutuzumab + Calcineurin Inhibitor to Corticosteroid + Cyclophosphamide treatment regimens in Primary Membranous Nephropathy
Purpose:
Primary Membranous Nephropathy is a kidney disease that causes leakage of protein in the urine and consequently severe swelling of the body. Some patients develop kidney failure. Currently, treatment involves giving corticosteroid and cyclophosphamide. Unfortunately, this treatment has many undesirable side effects. Hence, we need to find better treatment with less side effects. This trial will compare new treatment comprising of obinutuzumab and calcineurin inhibitor to the old treatment.
GO ID:
GO Title:
MRFF 2021 Rare Cancers Rare Diseases Unmet Need General - Grant Opportunity
Internal Reference ID:
2021/MRF2014850
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The University of Adelaide
Recipient ABN:
61 249 878 937
Grant Recipient Location
Suburb:
Adelaide
Town/City:
Adelaide
Postcode:
5000
State/Territory:
SA
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
SA, QLD
Postcode:
Multiple
Country:
AUSTRALIA